GILD - Gilead Sciences Inc Stock Price, Fair Value and News

$124.99+1.08 (+0.87%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GILD Price Action

Last 7 days

-2.0%

Last 30 days

2.4%

Last 90 days

10.8%

Trailing 12 Months

35.1%

GILD RSI Chart

GILD Valuation

Market Cap

155.1B

Price/Earnings (Trailing)

19.12

Price/Sales (Trailing)

5.33

EV/EBITDA

16.55

Price/Free Cashflow

16.93

GILD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GILD Fundamentals

GILD Revenue

Revenue (TTM)

29.1B

Rev. Growth (Yr)

2.97%

Rev. Growth (Qtr)

9.7%

GILD Earnings

Earnings (TTM)

8.1B

Earnings Growth (Yr)

143.58%

Earnings Growth (Qtr)

55.71%

GILD Profitability

EBT Margin

33.99%

Return on Equity

37.8%

Return on Assets

13.86%

Free Cashflow Yield

5.91%

GILD Investor Care

Dividend Yield

2.51%

Dividend/Share (TTM)

3.14

Buy Backs (1Y)

0.45%

Diluted EPS (TTM)

6.46

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	28.7B	28.9B	29.1B	0
2024	27.4B	27.8B	28.3B	28.8B
2023	27.0B	27.4B	27.4B	27.1B
2022	27.5B	27.5B	27.1B	27.3B
2021	25.6B	26.6B	27.5B	27.3B
2020	22.7B	22.2B	23.1B	24.7B
2019	22.3B	22.4B	22.4B	22.4B
2018	24.7B	23.2B	22.3B	22.1B
2017	29.1B	28.5B	27.5B	26.1B
2016	32.8B	32.4B	31.6B	30.4B
2015	27.5B	29.2B	31.4B	32.6B
2014	13.7B	17.4B	20.7B	24.9B
2013	10.0B	10.3B	10.7B	11.2B
2012	8.7B	9.0B	9.3B	9.7B
2011	7.8B	8.0B	8.2B	8.4B
2010	0	0	0	7.9B

Get all data in R, Python etc through our Historical Stock Data APIs

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

CEO	Mr. Daniel P. O'Day
WEBSITE	gilead.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	17000

Gilead Sciences Inc Frequently Asked Questions

What is the ticker symbol for Gilead Sciences Inc? What does GILD stand for in stocks?

GILD is the stock ticker symbol of Gilead Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gilead Sciences Inc (GILD)?

As of Wed Dec 03 2025, market cap of Gilead Sciences Inc is 155.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GILD stock?

You can check GILD's fair value in chart for subscribers.

Is Gilead Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether GILD is over valued or under valued. Whether Gilead Sciences Inc is cheap or expensive depends on the assumptions which impact Gilead Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GILD.

What is Gilead Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, GILD's PE ratio (Price to Earnings) is 19.12 and Price to Sales (PS) ratio is 5.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GILD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Gilead Sciences Inc's stock?

In the past 10 years, Gilead Sciences Inc has provided 0.018 (multiply by 100 for percentage) rate of return.